原发性骨质疏松症(primary osteoporosis,POP)是老年男性及绝经后女性常见的退行性骨代谢疾病,其并发症所导致的致残率或致死率已成为全球公共难题。骨保护素(osteoprotegerin,OPG)/核因子-κB受体活化因子配体(receptor activator of nuclear factor-κB ligand,RANKL)/核因子-κB受体活化因子(receptor activator of nuclear factor-κB,RANK)信号通路与骨代谢有着密切的联系。中药通过该信号通路治疗POP具有明显的优势,尤以补肾类中药最为突出。但是,关于补肾中药基于该信号通路治疗POP的调节机制仍然缺乏相对全面且系统的归纳总结。因此,基于OPG/RANKL/RANK信号通路在骨代谢的调节机制,从单味中药及中药复方的角度综述补肾中药防治POP的作用机制,为今后POP相关基础及临床研究提供理论依据。

Primary osteoporosis (POP) is a common degenerative bone metabolic disease in elderly men and postmenopausal women, and its complications have become a global public problem in terms of disability and mortality. The osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) signaling pathway is closely related to bone metabolism. Traditional Chinese medicine have advantages in treatment of POP based on OPG/RANKL/RANK signaling pathway, especially traditional Chinese medicine tonifying kidney are the most prominent. However, there is still a lack of a comprehensive and systematic summary of the regulatory mechanism of this signaling pathway based on traditional Chinese medicine tonifying kidney in treatment of POP. Therefore, based on regulatory mechanism of OPG/RANKL/RANK signaling pathway in bone metabolism, mechanism of traditional Chinese medicine tonifying kidney in treatment of POP from the perspective of single traditional Chinese medicine and traditional Chinese medicine compound, so as to provide a theoretical basis for future basic and clinical research on POP.

R282.710.5

天津市卫生健康委员会中医中西医结合科研课题（2021105）；天津市应用基础与前沿技术研究计划项目（15JCQNJC12700）